Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Notch Signaling

Written/Edited by Dr. Stefan Pellenz, PhD

The highly-conserved Notch signaling pathway is unique, as both the Notch receptor and most of its respective ligands (canonically the DSL or Delta/Serrate/lag-2 family members) are transmembrane proteins attached to the cell surface. Therefore, Notch signaling is limited to interaction between adjacent cells.

Communication between adjacent cells is paramount, particularly during early development, when cell fate and function are yet to be determined. Notch signaling provides a method for cells to specify their own identity, and to simultaneously influence the role and identity of neighboring cells through lateral inhibition.

The core of the Notch signaling pathway involves two adjacent cells, one expressing a DSL family ligand, and the other expressing the Notch (the receptor). When receptor and ligand interact, two separate protease enzymes cleave Notch into extracellular and cytosolic components. ADAM proteases cleave the extracellular portion of Notch, which remains bound to its respective ligand and is endocytosed by the signaling cell. γ-secretase cleaves the cytosolic portion of notch. This cytosolic region migrates to the nucleus where it binds to the transcription factor CSL, transforming it from a transcriptional repressor to an activator, and upregulating expression of Notch target genes.

Recent research has unveiled significant insights into the Notch signaling pathway, highlighting its complex roles in various biological processes and diseases. Notch signaling exhibits both oncogenic and tumor-suppressive functions, varying by cancer type and cellular context. For example, in prostate cancer, Notch acts as an oncogene in early stages but shifts to a tumor suppressor role during progression to neuroendocrine prostate cancer. Additionally, the pathway plays a crucial role in regulating macrophage phenotypes within the tumor microenvironment, influencing tumor progression and metastasis. Targeting this pathway could enhance cancer treatment efficacy while advancing mathematical models of Notch-Delta signaling have provided new insights into tissue patterning and developmental biology.

Related Pathways and Resources


References:

  • Bray: "Notch signalling: a simple pathway becomes complex." in: Nature reviews. Molecular cell biology, Vol. 7, Issue 9, pp. 678-89, (2006) (PubMed).
  • Ehebauer, Hayward, Martinez-Arias: "Notch signaling pathway." in: Science's STKE : signal transduction knowledge environment, Vol. 2006, Issue 364, pp. cm7, (2007) (PubMed).
  • Kopan, Ilagan: "The canonical Notch signaling pathway: unfolding the activation mechanism." in: Cell, Vol. 137, Issue 2, pp. 216-33, (2009) (PubMed).
  • Takebe, Nguyen, Yang: "Targeting notch signaling pathway in cancer: clinical development advances and challenges." in: Pharmacology & therapeutics, Vol. 141, Issue 2, pp. 140-9, (2014) (PubMed).
  • Zhang, Wang, Wu, Tang, Wang, Yang, Yao, Zhang: "Notch signaling pathway: a new target for neuropathic pain therapy." in: The journal of headache and pain, Vol. 24, Issue 1, pp. 87, (2023) (PubMed).

Notch

Notch Antagonists

FBXW7 (F-Box and WD Repeat Domain Containing 7):

NEDD4 (Neural Precursor Cell Expressed, Developmentally Down-Regulated 4, E3 Ubiquitin Protein Ligase):

Notch Ligands

Notch Processing

FURIN (Furin (Paired Basic Amino Acid Cleaving Enzyme)):

LFNG (LFNG O-Fucosylpeptide 3-beta-N-Acetylglucosaminyltransferase):

POFUT1 (Protein O-Fucosyltransferase 1):

POGLUT1 (Protein O-Glucosyltransferase 1):

RFNG (RFNG O-Fucosylpeptide 3-beta-N-Acetylglucosaminyltransferase):

Notch Directed Proteases

Pathway Agonists

Transcription Factors

KCNJ5 (Potassium Inwardly-Rectifying Channel, Subfamily J, Member 5):

MAML1 (Mastermind-Like 1):

RBPJ (Recombination Signal Binding Protein For Immunoglobulin kappa J Region):

NCOR2 (Nuclear Receptor Co-Repressor 2):

You are here:
Support